Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 4/20 | 0.58 |
| ▸ | CA2 | P00918 | 2/20 | 0.58 |
| ▸ | CA7 | P43166 | 2/20 | 0.58 |
| ▸ | CA9 | Q16790 | 2/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.50 |
| ▸ | HMGCR | P04035 | 1/20 | 0.48 |
| ▸ | MMP12 | P39900 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | CA4 | P22748 | 1/20 | 0.45 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4265169 | 1.00 | CA1 (0.58) | CA1CA2CA7CA9NPC1 | |
| SCHEMBL4668694 | 1.00 | CA1 (0.58) | CA1CA2CA7CA9NPC1 | |
| SCHEMBL8114468 | 1.00 | CA1 (0.58) | CA1CA2CA7CA9NPC1 | |
| SCHEMBL4842363 | 0.92 | CA1 (0.64) | CA1CA2CA7CA9NPC1 | |
| SCHEMBL4836421 | 0.92 | CA1 (0.64) | CA1CA2CA7CA9NPC1 | |
| SCHEMBL4836414 | 0.92 | CA1 (0.64) | CA1CA2CA7CA9NPC1 | |
| SCHEMBL9466787 | 0.86 | CA1 (0.54) | CA1CA2CA7CA9NPC1 | |
| SCHEMBL2216473 | 0.83 | CA1 (0.50) | CA1CA2CA7CA9NPC1 | |
| SCHEMBL2340083 | 0.82 | CA1 (0.51) | CA1CA2CA7CA9NPC1 | |
| SCHEMBL6482663 | 0.82 | CA1 (0.51) | CA1CA2CA7CA9NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0577040-B1 | Process for the preparation of (3R,5S)-6-hydroxy-3,5-O-isopropylidene-3,5-dihydroxy-hexanoic acid, tert.-butyl ester | HOECHST AG (DE) | 1997-09-24 | — | — | EP | claimed |
| US-10544119-B2 | Preparation method for chiral intermediate for use in statins | ASYMCHEM LABORATORIES (TIANJIN) CO., LTD. (CN) | 2020-01-28 | — | — | US | disclosed |
| EP-3141544-B1 | PREPARATION METHOD FOR CHIRAL INTERMEDIATE FOR USE IN STATINS | ASYMCHEM LABORATORIES (TIANJIN) CO LTD (CN) | 2018-02-07 | — | — | EP | disclosed |
| US-20170190684-A1 | PREPARATION METHOD FOR CHIRAL INTERMEDIATE FOR USE IN STATINS | ASYMCHEM LABORATORIES (TIANJIN) CO., LTD. (CN) | 2017-07-06 | — | — | US | disclosed |
| EP-3141544-A1 | PREPARATION METHOD FOR CHIRAL INTERMEDIATE FOR USE IN STATINS | Asymchem Laboratories (Tianjin) Co., Ltd (CN) | 2017-03-15 | — | — | EP | disclosed |
| WO-2002096915-A1 | PROCESS FOR PRODUCING OPTICALLY PURE Δ - HYDROXY-Β -KETOESTER DERIVATIVES | SAMSUNG FINE CHEMICALS CO., LTD. (KR) | 2002-12-05 | — | — | WO | disclosed |
| EP-0569998-B1 | Stereoselective microbial or enzymatic reduction of 3,5-dioxoesters to 3,5-dihydroxyesters | SQUIBB & SONS INC (US) | 2000-12-06 | — | — | EP | disclosed |
| EP-0583171-B1 | (3R,5S)-3,5,6-trihydroxyhexanoic acid derivatives and methods for their production | TAKASAGO PERFUMERY CO LTD (JP) | 1998-11-11 | — | — | EP | disclosed |
| US-5324662-A | Chemical intermediate for anticholesterol agent | E. R. SQUIBB & SONS, INC. (US) | 1994-06-28 | — | — | US | disclosed |
| EP-0583171-A2 | (3R,5S)-3,5,6-trihydroxyhexanoic acid derivatives and methods for their production | Takasago International Corporation (JP) | 1994-02-16 | — | — | EP | disclosed |
| US-5286883-A | (3R,5S)-3,5,6-trihydroxyhexanoic acid derivative and production method thereof | TAKASAGO INTERNATIONAL CORPORATION (JP) | 1994-02-15 | — | — | US | disclosed |
| EP-0569998-A2 | Stereoselective microbial or enzymatic reduction of 3,5-dioxo esters to 3-hydroxy-5-oxo, 3-oxo-5-hydroxy, and 3,5-dihydroxy esters | E.R. SQUIBB & SONS, INC. (US) | 1993-11-18 | — | — | EP | disclosed |
| US-4985571-A | 6-membered lactones useful as intermediates for antilipemic mevalonic acid lactones | Takano, Seiichi (JP) | 1991-01-15 | — | — | US | disclosed |
| EP-0362628-A2 | 6-Membered lactones and process for their production | Takano, Seiichi (JP) | 1990-04-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190684-A1 | PREPARATION METHOD FOR CHIRAL INTERMEDIATE FOR USE IN STATINS | HMGCR, COASY, CETP | CA1 874/4885CA2 600/4885CA7 340/4885 |
| US-10544119-B2 | Preparation method for chiral intermediate for use in statins | HMGCR, COASY, CETP | CA1 874/4885CA2 600/4885CA7 340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.